{"filings":[{"id":1204797,"accession_number":"0000899923-26-000062","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-06-23T12:32:15+00:00","items":["5.02"],"status":"ready","headline":"Myriad Genetics director Daniel M. Skovronsky resigns effective June 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel M. Skovronsky resigned from Myriad Genetics board effective June 17, 2026.","Resignation was not due to any disagreement with the company or its operations.","Myriad Genetics (MYGN) filed Form 8-K on June 23, 2026 to report the departure.","Skovronsky served as a director prior to resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861038,"accession_number":"0000899923-26-000059","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-06-04T20:08:53+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Myriad Genetics shareholders approve equity plan amendments, elect directors at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved amendment to ESPP increasing authorized shares by 4,000,000.","Approved 2026 Equity Incentive Plan with total reserve of 8,463,567 shares.","Elected Class III directors Paul Bisaro, Rashmi Kumar, Lee Newcomer with over 60M votes each.","Ratified Ernst & Young as independent auditor for 2026 with 76.3M for, 1.4M against.","Advisory vote approved executive compensation with 59.4M for, 3.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99601,"accession_number":"0000899923-26-000036","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.","Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.","Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.","Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.","Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":200400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115701,"accession_number":"0000899923-26-000012","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.","Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.","Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.","Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.","Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":824500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115700,"accession_number":"0000899923-26-000003","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.","Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.","FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).","FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).","Formal Q4/FY 2025 earnings call scheduled for February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":824500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132131,"accession_number":"0000899923-25-000109","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K/A","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).","GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.","Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.","Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.","Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":614700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132134,"accession_number":"0000899923-25-000103","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.","GAAP net loss $27.4M ($0.29 per share); adjusted EPS $0.00; adjusted EBITDA $10.3M.","Hereditary cancer testing volume +11% YoY, revenue +3%; pharmacogenomics revenue -19% due to UnitedHealthcare coverage discontinuation.","Gross margin 69.9%; cash and equivalents $145.4M as of Sept 30, 2025.","Entered strategic collaboration with SOPHiA GENETICS for global liquid biopsy companion diagnostic development."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":614700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132133,"accession_number":"0000899923-25-000096","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics finalizes separation agreement with former CFO Scott Leffler; $1.24M severance plus equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott J. Leffler's separation effective Sep 2, 2025; lump-sum severance payment of $1,239,384.","Unvested time-based equity awards scheduled to vest within 2 years accelerated; performance-based awards remain outstanding.","COBRA medical premiums paid by company for up to one year after separation date.","Leffler reaffirms non-compete, non-solicitation, and non-disparagement obligations.","Company provides neutral references; no admission of liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132132,"accession_number":"0000899923-25-000091","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Myriad Genetics principal accounting officer Natalie Munk to resign; CFO Wheeler to assume role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Natalie Munk resigns as SVP, Chief Accounting Officer and principal accounting officer; effective October 24, 2025.","Departure is not due to any disagreement with the Company on operations, policies, or practices.","CFO Benjamin R. Wheeler designated as principal accounting officer effective on Munk's departure date.","Wheeler, 42, has been with Myriad for 13 years, including CFO since August 2025, and holds a CPA from BYU.","Wheeler will not receive any additional compensation for the additional role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148702,"accession_number":"0000899923-25-000089","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics appoints Ben Wheeler as CFO; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Leffler stepped down as CFO effective Aug 15, 2025; will consult through Sept 2, 2025.","Ben Wheeler appointed CFO effective Aug 16, 2025; previously SVP, CFO of Operations for 13 years.","Wheeler receives $490,000 base salary, 75% bonus target, and 120,000 RSUs (60k time, 60k performance).","Full-year 2025 financial guidance reaffirmed as announced on Aug 5, 2025 Q2 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148701,"accession_number":"0000899923-25-000084","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.","Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.","Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.","New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.","GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":409000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148700,"accession_number":"0000899923-25-000072","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.","Interest rate of one-month SOFR + 6.50%, with a 2.50% SOFR floor; matures July 31, 2030.","Proceeds for working capital, general corporate purposes, and refinancing existing ABL facility.","Credit facility is secured by substantially all assets of Myriad and its subsidiaries.","Company now has access to over $200M in capital (including cash) to support growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167579,"accession_number":"0000899923-25-000066","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Myriad shareholders approve 6.5M share increase to 2017 equity plan; per-participant cap raised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan adding 6.5 million shares for equity grants.","Board increased annual per-participant share cap from 500,000 to 574,040 shares.","All three director nominees (Raha, Dreismann, Reitan) elected with >97% of votes cast.","Advisory say-on-pay approved with 92% of votes cast in favor.","Ernst & Young ratified as auditor for fiscal 2025 with 95.6% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167578,"accession_number":"0000899923-25-000045","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.","Prenatal revenue grew 11% YoY; Pharmacogenomics revenue fell 20% due to UnitedHealthcare coverage cut for GeneSight.","Gross margin 69% (+40 bps YoY) on lab efficiencies; operating loss $29M vs $27.9M YoY.","Updated FY2025 revenue guidance lowered to $807-823M from $840-860M; adjusted EPS now $(0.02)-$0.02.","CEO cited challenges in GeneSight and unaffected hereditary cancer; taking steps to reduce costs and drive growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":195900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184864,"accession_number":"0000899923-25-000010","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.","Mark S. Verratti promoted to COO effective April 30, succeeding Raha.","Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).","Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.","Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184863,"accession_number":"0000899923-25-000002","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.","Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.","Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.","FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.","FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":837600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201459,"accession_number":"0000899923-24-000065","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics appoints Mark S. Davis to Board, expanding to nine members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Davis appointed as Class I Director effective December 10, 2024, expanding Board from eight to nine.","Davis will serve on Audit and Finance Committee; deemed independent and an audit committee financial expert.","Received restricted stock unit award of $350,000 vesting one year from grant date.","Davis spent nearly 40 years at Deloitte & Touche LLP, last as National Managing Partner of Deloitte Private.","Also serves on boards of Yext, Inc., NYU-Winthrop Hospital, and Adelphi University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201458,"accession_number":"0000899923-24-000060","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics derivative lawsuit settled; court approves $950k fee award, dismisses claims with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approves global settlement of shareholder derivative litigation; no admission of liability.","Company pays $950,000 in attorneys' fees and expenses; adopts corporate governance reforms.","Consolidated Delaware derivative actions and federal derivative action dismissed with prejudice.","Settlement relates to complaints alleging fiduciary duty breaches by former and current directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201457,"accession_number":"0000899923-24-000054","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.","GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.","FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.","UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.","GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":627000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201456,"accession_number":"0000899923-24-000048","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2024 revenue expected between $210M and $212M.","Full-year 2024 revenue guidance reaffirmed at $835M-$845M.","Divestiture of EndoPredict business in Europe closed on August 1, 2024.","Results are preliminary and unaudited; subject to finalization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":627000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217459,"accession_number":"0000899923-24-000045","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.","Part two aimed to compare GeneSight patients vs. matched non-GeneSight control; significant baseline disparities made control group non-viable.","Company concluded data comparing the two groups were not reliable and halted the analysis.","GeneSight's causal role in hospitalization reduction remains unconfirmed without a valid control group.","Company plans to publish full part one results in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217458,"accession_number":"0000899923-24-000036","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).","Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.","Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.","Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.","Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":413700000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237335,"accession_number":"0000899923-24-000028","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myriad Genetics stockholders elect two directors, ratify auditor, approve advisory compensation vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["S. Louise Phanstiel and Daniel M. Skovronsky elected as directors for terms expiring 2027.","Ernst & Young ratified as independent auditor for FY 2024 with 81.5M votes for, 2.9M against.","Advisory vote on executive compensation approved with 74.4M for, 4.1M against.","Approximately 93% of outstanding shares present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237334,"accession_number":"0000899923-24-000027","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics settles shareholder derivative suit; pays up to $950k in fees, adopts governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves claims that officers misled investors about GeneSight efficacy and study compliance.","Myriad will adopt new disclosure committee charter, CCO job profiles, and amendments to several board committee charters.","Plaintiffs' counsel may seek up to $950,000 in attorneys' fees and costs, paid by Myriad or its insurers.","Court hearing on proposed settlement scheduled for August 6, 2024; defendants deny wrongdoing.","Governance reforms to remain in effect for at least four years from adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237333,"accession_number":"0000899923-24-000025","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.","Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.","Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).","Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.","Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":202200000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254869,"accession_number":"0000899923-24-000014","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).","Q4 GAAP EPS $(0.36); adjusted EPS $0.04, first positive adjusted EPS in recent quarters.","Q4 Hereditary Cancer revenue $88.9M (+5% YoY); Prenatal $40.0M (+37% YoY); GeneSight $35.6M (+11% YoY).","FY2024 revenue guidance raised to $820-840M (9-11% growth); adjusted EPS guidance $0.00-$0.05.","Acquired select assets from Intermountain Precision Genomics in Feb 2024, including Precise Tumor and Liquid tests."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":753200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254868,"accession_number":"0000899923-24-000005","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics prelim Q4 revenue $196-197M; GAAP EPS loss ($0.35)-($0.36); adjusted EPS $0.02-0.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 revenue $196-197M; GAAP diluted EPS loss ($0.35)-($0.36); adjusted EPS $0.02-$0.03.","FY2023 revenue growth reaffirmed at least 10% YoY; prenatal volume growth at least 10% in Q4.","Reaffirmed positive adjusted operating cash flow in Q4 2023; guided estimated cash and credit at year-end.","Excluded items for non-GAAP: stock-based comp ~$10.3M, amortization ~$10.7M, transformation costs ~$14.1M, legal ~$0.6M, tax ~$2.0M.","Reaffirmed FY2023 revenue and non-GAAP guidance originally provided on Nov 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":753200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272356,"accession_number":"0000899923-23-000117","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics CFO Bryan Riggsbee retires; Scott Leffler named successor effective Jan 29, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Riggsbee steps down as CFO by Jan 31, 2024; will serve as strategic advisor through March 31, 2024.","New CFO Scott Leffler appointed effective Jan 29, 2024; previously CFO at Clover Health and Sotera Health.","Leffler receives base salary $550k, target bonus 75%, sign-on bonus $400k, and initial RSU grants totaling $2.5M.","Company reiterates 2023 and 2024 financial guidance previously issued on Nov 6, 2023.","Departure not due to disagreements; separation includes consulting fee $2,713.65/week and continued equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272355,"accession_number":"0000899923-23-000110","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Myriad Genetics raises ~$110M via public offering of 6.47M shares at $17/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered underwriting agreement with Goldman Sachs, Morgan Stanley, and Wells Fargo to sell 6,470,588 shares at $17.00/share.","Underwriters have a 30-day option to purchase up to 970,588 additional shares.","Offering closed on November 13, 2023; net proceeds after underwriting discounts and commissions not specified.","Prospectus supplement filed under automatic shelf registration statement (File No. 333-275396)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272354,"accession_number":"0000899923-23-000102","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myriad Genetics prices upsized 6.47M-share offering at $17.00 for ~$110M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,470,588 shares upsized; priced at $17.00/share; expected gross proceeds ~$110M.","Underwriters granted 30-day option for up to 970,588 additional shares at same price.","Net proceeds: ~$40M to repay asset-based revolving credit facility; ~$57.5M to settle securities class action (In re Myriad Genetics).","Remainder for working capital and general corporate purposes; closing expected Nov 13, 2023.","Goldman Sachs, Morgan Stanley, and Wells Fargo acting as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272353,"accession_number":"0000899923-23-000083","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.","Testing volume ex-SneakPeek +18% YoY; hereditary cancer +18%, prenatal +20%, GeneSight +19%.","Raised FY2023 revenue guidance to $747-753M (prev $730-750M); introduced FY2024 guidance $815-835M.","Settled Ravgen litigation for $12.75M plus contingent $21.25M; expanded credit facility to $115M.","New UnitedHealthcare contract effective Jan 1, 2024 through 2027; appointed Sam Raha COO effective Dec 11."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":556600000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272352,"accession_number":"0000899923-23-000075","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics appoints Sam Raha as COO effective Dec 11, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $750k; annual target cash bonus 75% of base; sign-on bonus $500k with clawback provisions.","Initial RSU grant of $4M (two tranches of $2M each based on stock price at hiring announcement and start date).","Eligible for additional RSU grant of $2-3M in 2024, 50% time-vesting and 50% performance-vesting.","Raha previously President of Agilent Diagnostics & Genomics Group and VP Global Marketing at Illumina.","Raha will oversee lab operations, customer service, and product development innovations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272351,"accession_number":"0000899923-23-000072","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["5.01","9.01"],"status":"ready","headline":"Myriad Genetics increases revolving credit facility by $25M to $115M, adds Goldman Sachs as lender","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility raised from $90M to $115M; $25M new commitment from Goldman Sachs Bank USA.","Amendment consents to South Chipeta lease assignment and sale of office furniture/equipment (value ≤$4.3M).","Extended deadline for compliance with certain post-closing obligations of the original credit agreement.","Loan parties reaffirm guarantees and security interests; Lien on South Chipeta personal property to be released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272350,"accession_number":"0000899923-23-000066","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Myriad Genetics secures multi-year UnitedHealthcare contract renewal through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement covers tests: MyRisk, MyChoice CDx, BRACAnalysis CDx, Foresight, Prequel, GeneSight, Prolaris.","Contract effective Jan 1, 2024 to Dec 31, 2027; specific pricing terms not disclosed.","Company reiterates long-term financial targets announced at Sep 19, 2023 investor day, consistent with this renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272349,"accession_number":"0000899923-23-000064","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics COO Nicole Lambert to step down Oct 31; remains consultant through Mar 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Nicole Lambert will depart as of Oct 31, 2023; will provide consulting services through Mar 31, 2024.","Lambert receives weekly consulting fee of $4,951.92 and continued equity vesting during consulting period.","Outstanding RSUs scheduled to vest within one year post-Separation Date will accelerate at Mar 31, 2024.","Company reaffirmed FY2023 revenue and non-GAAP guidance previously provided on Sep 19 investor day.","Departure not due to any disagreement with company's operations, policies, or procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289185,"accession_number":"0000899923-23-000052","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","3.02","8.01","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $183.5M, settles securities class action for $77.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $183.5M, up 2% YoY; diluted GAAP EPS $(1.42), adjusted EPS $(0.08).","Test volume grew 38% YoY (17% ex-SneakPeek); hereditary cancer volume up 20% YoY.","Agreed to settle securities class action for $77.5M: $20M cash in Q3 2023, remainder in cash or stock by Q1 2024.","Reaffirmed FY2023 revenue guidance $730-750M; adjusted EPS loss $(0.36)-(0.24); targeting positive adjusted profitability in Q4.","Established new $90M asset-based credit facility (option to $115M); ended Q2 with $127.8M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":364700000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289184,"accession_number":"0000899923-23-000047","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Myriad Genetics establishes new $90M asset-based credit facility expandable to $115M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $90M ABL Facility with option to increase by $25M to $115M; matures June 30, 2026.","Lenders: JPMorgan Chase (admin agent), Wells Fargo, Bank of America; secured by substantially all assets.","Proceeds for working capital, general corporate purposes, and refinancing existing debt.","Interest rate options: ABR plus 1.00%-1.50% or Term SOFR plus 2.00%-2.50% based on unused availability.","Replaces prior credit facility; CEO Paul Diaz cites added financial flexibility for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309952,"accession_number":"0000899923-23-000041","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Myriad Genetics shareholders approve equity plan increase and charter amendments at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer as directors for terms expiring 2026.","Approved amendment to 2017 Equity Plan to add 4.8 million shares for future grants.","Approved certificate amendments: federal forum selection clause and officer exculpation.","Ratified Ernst & Young as independent auditor for fiscal 2023.","Advisory vote approved executive compensation and favored annual frequency for future votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309951,"accession_number":"0000899923-23-000031","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).","Testing volumes +21% ex-SneakPeek; hereditary cancer +24%, GeneSight +31% YoY.","FY23 revenue guidance raised to $730-750M (previous $720-750M); gross margin 68-70% reaffirmed.","GAAP gross margin 67.3% (down 360bps YoY) due to product mix and $12.4M prior-year benefit.","Ended Q1 with $109.1M cash, no debt; management targets profitability by Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":181200000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328647,"accession_number":"0000899923-23-000008","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q4 revenue $177.8M (+11% YoY); GAAP EPS $(0.52), adjusted EPS $(0.12)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 testing volumes up 26% YoY; hereditary cancer +16%, GeneSight +23%.","Full-year 2022 GeneSight revenue grew 36% to $127.6M.","FY2023 guidance: revenue $720-750M, adjusted EPS $(0.40)-$(0.20).","Q1 2023 guidance: revenue $170-172M, adjusted EPS $(0.20)-$(0.18).","Ended Q4 with $169.7M cash, no debt; cash used in ops $7.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":678400000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346316,"accession_number":"0000899923-22-000137","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $156.4M, GAAP EPS $(0.43); cuts FY22 guidance; acquires Gateway Genomics for $67.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $156.4M (-2% YoY); GAAP EPS $(0.43), adjusted EPS $(0.19).","GeneSight volumes +34% YoY; hereditary cancer volumes +4% YoY; total testing volumes +12% ex-divestitures.","Acquired Gateway Genomics for $67.5M cash plus up to $32.5M earnout; Gateway expected to be accretive in 2024.","FY2022 revenue guidance cut to $668-672M (prev. $670-700M); adjusted EPS guided to $(0.35)-$(0.30).","Quarter-end cash $259.2M, no debt; operating cash flow -$2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":500600000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362718,"accession_number":"0000899923-22-000123","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.","GeneSight volumes up 39% YoY; hereditary cancer volumes down 4% YoY but stabilizing.","FY2022 revenue guidance unchanged at $670-$700M; adjusted EPS cut to $(0.10)-$0.00 from $0.00-$0.20.","Cash $283.6M; paid $48M qui tam settlement in Q2; no debt.","Launched Precise Oncology Solutions; liquid biopsy test via Illumina/Intermountain expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":344200000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362717,"accession_number":"0000899923-22-000112","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Myriad Genetics amends credit agreement: revolver cut to $200M, covenants waived through July 2023","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving commitments reduced from $300M to $200M, further to $150M by Dec 31, 2022; potential additional $50M cut from asset sales.","Leverage ratio and interest coverage ratio covenants waived through July 31, 2023, the maturity date of the credit facility.","Interest rate benchmark switched from LIBOR to SOFR; applicable margins and undrawn fees unchanged.","Monthly liquidity reporting required if total revolving exposure > $0 (net of LC exposure under $5M).","Lenders received a fee of 0.25% of their commitments for agreeing to the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382306,"accession_number":"0000899923-22-000096","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dennis Langer resigns from Myriad Genetics, enters consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dennis Langer resigned as director effective June 30, 2022, not due to any disagreement with the company.","Myriad Genetics and Langer entered a one-year consulting agreement effective upon resignation.","Consulting agreement provides for hourly compensation and continued vesting of equity awards during term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382305,"accession_number":"0000899923-22-000085","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Myriad Genetics names Natalie Munk principal accounting officer; shareholders OK ESPP expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Natalie Munk (CAO since July 2020) designated as principal accounting officer; Bryan Riggsbee remains CFO.","Shareholders approved amended ESPP, increasing authorized shares by 2M and extending term to November 2032.","Directors Diaz, Dreismann, and Reiten elected to 2025 terms; each received >66M votes in favor.","Ernst & Young ratified as independent auditor for FY2022 with 71.1M votes for (3.4M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382304,"accession_number":"0000899923-22-000068","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 2022 revenue $164.9M, GAAP EPS -$0.26, adjusted EPS -$0.03; reiterates FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $164.9M (+11% YoY ex-divested); GAAP EPS $(0.26) improved from $(0.52); adjusted EPS $(0.03) from $(0.06).","Cash $339.2M, no debt; adjusted gross margin 71.1%, operating loss $2.8M improved from $3.3M.","Segment: Hereditary cancer rev $70.9M (-7% YoY); Pharmacogenomics rev $29.3M (+66% YoY); Prenatal +35%.","Reiterated FY2022 guidance: rev $670-700M; GAAP EPS $(0.90)-(0.70); adj EPS $0.00-$0.20.","Launched Precise Tumor test, expanded MyRisk to 13 genes, partnered on liquid biopsy test."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":164900000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382303,"accession_number":"0000899923-22-000036","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Myriad Genetics settles Vectra test qui tam case for $48M ($45.25M to govt, $2.75M to relator)","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Total settlement of $48 million: $45.25M to United States and California, $2.75M to Relator's counsel.","No admission of liability; company expressly denies allegations in the lawsuit.","DOJ and State of California declined to intervene after investigation.","Lawsuit dismissed with prejudice as to Relator and California; federal claims dismissed without prejudice.","Settlement resolves claims concerning Crescendo's former Vectra test dating back to 2010."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400235,"accession_number":"0000899923-22-000022","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q4 revenue up 4% to $160.8M; GAAP EPS $(0.10), adjusted $(0.02)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $160.8M (+4% YoY); full-year $690.6M (+24%). Ex-divested businesses, Q4 revenue up 19%.","GAAP diluted EPS $(0.10); adjusted EPS $(0.02); GAAP gross margin 71.5%, adjusted 71.8%.","Hereditary cancer revenue $74.8M (-5% YoY); pharmacogenomics $29.4M (+63%); prenatal $30.1M (+43%).","FY2022 guidance: revenue $670-700M, adjusted EPS $0.00-$0.20, adjusted gross margin 70-72%.","Ended Q4 with $398.8M cash, no debt; Omicron variant adversely impacted hereditary cancer volumes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":690600000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400234,"accession_number":"0000899923-22-000014","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics CSO Jerry Lanchbury retires; severance $782k plus equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerry Lanchbury retired as Chief Scientific Officer effective Jan 14, 2022, will consult through Mar 31, 2022.","Lump sum severance of $782,276.93; weekly consulting fee of $500; additional $45,401.67 possible at end.","Unvested equity awards scheduled to vest within two years of transition are accelerated, with performance-based awards subject to conditions.","Non-compete and non-solicitation covenants apply for 12 months after the consulting period.","Eligible for 2021 annual bonus as determined by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400233,"accession_number":"0000899923-22-000009","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics expects ~$400M cash on hand, no debt entering 2022","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Paul Diaz presented at 40th Annual J.P. Morgan Health Care Conference on Jan 11, 2022.","Company expects to start 2022 with approximately $400M in cash, cash equivalents, and marketable securities.","Preliminary unaudited FY2021 financial data not finalized; adjustments could be material.","Company reports no debt, highlighting strong liquidity position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-11T23:59:59+00:00|400233"}